Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM958EN)

Drug Name

8-Piperazin-1-yl-imidazo[1,2-a]pyrazine Drug Info

Synonyms

76537-53-6; 8-(1-Piperazinyl)imidazo(1,2-a)pyrazine; 8-(1-piperazinyl)imidazo[1,2-a]pyrazine; CHEMBL331036; 8-piperazin-1-ylimidazo[1,2-a]pyrazine; 8-Pdpr; Imidazo(1,2-a)pyrazine, 8-(1-piperazinyl)-; Imidazo[1,2-a]pyrazine, 8-(1-piperazinyl)-; 8-Piperazin-1-yl-imidazo[1,2-a]pyrazine; AC1L2YVL; 8-(piperazin-1-yl)imidazo[1,2-a]pyrazine; AC1Q4X6M; SCHEMBL5496661; AC1Q1I52; CTK5E3085; DTXSID50227346; ZINC5117657; BDBM50002151; AKOS024075563; FT-0756627; Imidazo[1,2-a]pyrazine,8-(1-piperazinyl)-; A839966

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 131268
CAS Number: CAS 76537-53-6
TTD Drug ID: DM958EN

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Adrenergic receptor alpha-1D (ADRA1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxazosin	DM9PLRH	Benign prostatic hyperplasia	GA90	Approved	[2]
Armodafinil	DMGB035	Malignant glioma	2A00.0	Approved	[3]
Alfuzosin	DMZVMKF	Benign prostatic hyperplasia	GA90	Approved	[4]
Moxisylyte	DMFCLYW	Erectile dysfunction	HA01.1	Approved	[5]
Terazosin	DM3JCVS	Benign prostatic hyperplasia	GA90	Approved	[6]
Bunazosin	DM4I8O7	Glaucoma/ocular hypertension	9C61	Approved	[7]
Trimazosin	DM1QLST	Congestive heart failure	BD10	Approved	[8]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[9]
DL-017	DMM8GZT	Hypertension	BA00-BA04	Phase 1	[10]
PMID30124346-Compound-LDT8	DM5MUNG	Benign prostatic hyperplasia	GA90	Patented	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Adrenergic receptor alpha-1A (ADRA1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SILODOSIN	DMJSBT6	Benign prostatic hyperplasia	GA90	Approved	[12]
NAFTOPIDIL	DMQ8R4E	Hypertension	BA00-BA04	Approved	[12]
Tamsulosin	DM5QF9V	Benign prostatic hyperplasia	GA90	Approved	[13]
Xatral	DMLHOA0	Benign prostatic hyperplasia	GA90	Approved	[14]
Dutasteride + tamsulosin	DM6P8HU	Benign prostatic hyperplasia	GA90	Phase 3	[15]
Besipirdine	DMLVNTA	Cognitive impairment	6D71	Phase 3	[16]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[9]
PMID30124346-Compound-LDT8	DM5MUNG	Benign prostatic hyperplasia	GA90	Patented	[11]
PMID30124346-Compound-LDT66	DMJMTNL	Benign prostatic hyperplasia	GA90	Patented	[11]
TIOSPIRONE	DME5QDP	N. A.	N. A.	Discontinued in Phase 3	[17]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-1A (ADRA1A)	TTNGILX	ADA1A_HUMAN	Inhibitor	[1]
Adrenergic receptor alpha-1D (ADRA1D)	TT34BHT	ADA1D_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines. J Med Chem. 1992 Oct 16;35(21):3845-57.
2	The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
3	Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
4	Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
5	Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
6	Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
7	Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
8	The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
9	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
10	Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
11	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
12	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
13	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
14	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
15	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
16	Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
17	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.